{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:09:45Z","timestamp":1785247785326,"version":"3.55.0"},"reference-count":212,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015495","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T10:25:28Z","timestamp":1723544728000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer"],"prefix":"10.1002","volume":"2024","author":[{"given":"Emeline","family":"Orillard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; University Hospital of Besan\u00e7on; Besan\u00e7on France"},{"name":"EFS, INSERM, UMR RIGHT; Universit\u00e9 de Franche-Comt\u00e9, CHU Besan\u00e7on; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjab","family":"Adhikari","sequence":"additional","affiliation":[{"name":"Internal Medicine; Ascension Saint Francis Hospital; Evanston Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem S","family":"Malouf","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Calais","sequence":"additional","affiliation":[{"name":"Biblioth\u00e8que Universitaire de Sant\u00e9; Universit\u00e9 de Franche-Comt\u00e9; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corynne","family":"Marchal","sequence":"additional","affiliation":[{"name":"SAIC; Universit\u00e9 de Franche-Comt\u00e9; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[{"name":"EFS, INSERM, UMR RIGHT; Universit\u00e9 de Franche-Comt\u00e9, CHU Besan\u00e7on; Besan\u00e7on France"},{"name":"Department of Chest Diseases and Thoracic Oncology; University Hospital of Besan\u00e7on; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD015495-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S927","DOI":"10.1016\/j.jtho.2021.08.181","article-title":"CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC","volume":"16","author":"Wang","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"36 Suppl","key":"10.1002\/14651858.CD015495-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"362936","DOI":"10.1200\/JCO.2022.40.36_suppl.362936","article-title":"Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with firstline chemotherapy for advanced NSCLC without EGFR\/ALK mutations","volume":"40","author":"Wang","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD015495-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015495-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2019.37.15_suppl.9013","article-title":"KEYNOTE-189: updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum versus placebo plus chemo for metastatic nonsquamous NSCLC","volume":"37","author":"Gadgeel","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"16 suppl","key":"10.1002\/14651858.CD015495-BIB0006|cit6","first-page":"LB","article-title":"Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by STK11 and KEAP1 status","volume":"80","author":"Gadgeel","year":"2020","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD015495-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Gandhi L Rodgriguez-Abreu D Gadgeel S Esteban E Felmip E De Angelis F KEYNOTE-189: randomized, doubleblind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC Cancer Research 2018 78 13 Suppl CT075 10.1158\/1538-7445.AM2018-CT075","DOI":"10.1158\/1538-7445.AM2018-CT075"},{"issue":"22","key":"10.1002\/14651858.CD015495-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015495-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.jtho.2019.08.427","article-title":"OA04.06 Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for non-squamous NSCLC","volume":"14","author":"Garassino","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015495-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.jtho.2018.07.026","article-title":"PD.1.01 health-related quality of life with pembrolizumab or placebo + pemetrexed + platinum in non-squamous NSCLC: KEYNOTE-189","volume":"13","author":"Garassino","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015495-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.jtho.2019.09.129","article-title":"PD2.02 Pembrolizumab plus pemetrexed-platinum for patients with metastatic nonsquamous NSCLC and liver or brain metastases: results from KEYNOTE-189","volume":"14","author":"Garassino","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"issue":"13 Suppl","key":"10.1002\/14651858.CD015495-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"CT043","DOI":"10.1158\/1538-7445.AM2019-CT043","article-title":"Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: results from the KEYNOTE-189 study","volume":"79","author":"Garassino","year":"2019","journal-title":"Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD015495-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","article-title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015495-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1992-8","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in non squamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S992-3","DOI":"10.1016\/j.annonc.2022.07.1101","article-title":"KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum versus placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC","volume":"33","author":"Garassino","year":"2022","journal-title":"Annals of Oncology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015495-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1016\/j.jtho.2021.01.141","article-title":"FP13.02 Pembrolizumab + pemetrexed-platinum versus pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189","volume":"16","author":"Gray","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Hall RD Gadgeel SM Garon EB Bria E Reck M Via J Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): kEYNOTE-189 Journal of Clinical Oncology 2016 34 15 Suppl TPS9104","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS9104"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015495-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"ii56","DOI":"10.1093\/annonc\/mdz063.049","article-title":"Safety and tolerability of pembrolizumab or placebo plus pemetrexed and platinum as first-line therapy in Japanese patients (PTS) with metastatic non-squamous non-small cell lung cancer (NSCLC) enrolled in the phase III KEYNOTE-189 study","volume":"30","author":"Horinouchi","year":"2019","journal-title":"Annals of Oncology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD015495-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"ix164","DOI":"10.1093\/annonc\/mdy425.042","article-title":"KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: does choice of platinum affect outcomes?","volume":"29","author":"Rodriguez Abreu","year":"2018","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015495-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic non squamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodriguez-Abreu","year":"2021","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015495-BIB0021|cit21","first-page":"100104","article-title":"Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): eMPOWER-Lung 3 part I","volume":"16","author":"Baramidze","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial","volume":"28","author":"Gogishvili","year":"2022","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S1567-8","DOI":"10.1016\/j.annonc.2022.10.361","article-title":"EMPOWER-Lung 3: cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)","volume":"33","author":"Gogishvili","year":"2022","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015495-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S649","DOI":"10.1016\/j.jtho.2019.08.1370","article-title":"P2.01-26 EMPOWER-Lung 3: phase 3 study of combinations of cemiplimab and chemotherapy in first-line treatment of advanced NSCLC","volume":"14","author":"Gogishvili","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S983","DOI":"10.1016\/j.annonc.2022.07.1080","article-title":"Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): eMPOWER-Lung 3 subgroup analysis","volume":"33","author":"Kalinka-Warzocha","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"755\u201368","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: 2-year follow-up from the Phase 3 EMPOWER-Lung 3 Part 2 trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S38-S39","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"50 Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: longer follow-up results from the phase III EMPOWER-Lung 3 trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0028|cit28","unstructured":"Combinations of cemiplimab (anti-PD-1 antibody) and platinum-based doublet chemotherapy in patients with lung cancer clinicaltrials.gov\/ct2\/show\/NCT03409614"},{"issue":"10","key":"10.1002\/14651858.CD015495-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"S931","DOI":"10.1016\/j.jtho.2018.08.1732","article-title":"EMPOWER-Lung 3: a Phase 3 study of cemiplimab, ipilimumab and chemotherapy in advanced NSCLC with PD-L1 <50%","volume":"13","author":"Rizvi","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"30","key":"10.1002\/14651858.CD015495-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer","volume":"35","author":"Govindan","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015495-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S349-50","DOI":"10.1016\/j.jtho.2022.07.599","article-title":"Durvalumab (D) \u00b1 tremelimumab (T) + chemotherapy (CT) in 1L metastatic NSCLC: outcomes by tumour PD-L1 expression in POSEIDON","volume":"17","author":"Garon","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015495-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"11 Suppl 2","key":"10.1002\/14651858.CD015495-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"S1975","DOI":"10.1016\/j.jtho.2017.09.867","article-title":"Poseidon: a phase 3 study of first-line durvalumab \u00b1 tremelimumab + chemotherapy versus chemotherapy alone in metastatic NSCLC","volume":"12","author":"Mok","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000492737","article-title":"POSEIDON: a phase 3 study of first-line durvalumab \u00b1 tremelimumab + chemotherapy versus chemotherapy alone in metastatic NSCLC","volume":"41","author":"Thomas","year":"2018","journal-title":"Oncology Research and Treatment"},{"issue":"10 suppl","key":"10.1002\/14651858.CD015495-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1016\/j.jtho.2019.08.484","article-title":"OA14.02 IMpower131: final OS results of carboplatin + nab-paclitaxel \u00b1 atezolizumab in advanced squamous NSCLC","volume":"14","author":"Jotte","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD015495-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"issue":"19 Suppl","key":"10.1002\/14651858.CD015495-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"LBA9000","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA9000","article-title":"IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC","volume":"36","author":"Jotte","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0038|cit38","unstructured":"A phase III clinical study to evaluate the efficacy and safety of atezolizumab in combination with carboplatin+paclitaxel or atezolizumab in combination with carboplatin+nab-paclitaxel compared with carboplatin+nab-paclitaxel in patients with stage IV squamous non-small cell lung cancer (NSCLC) [IMpower131] clinicaltrials.gov\/ct2\/show\/NCT02367794 2015"},{"key":"10.1002\/14651858.CD015495-BIB0039|cit39","unstructured":"A phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of mpdl3280a (anti-pd-l1 antibody) in combination with carboplatin + paclitaxel or mpdl3280a in combination with carboplatin + nab paclitaxel versus carboplatin + nab-paclitaxel in chemotherapy-naive patients with stage IV squamous non-small cell lung cancer trialsearch.who.int\/Trial2.aspx?TrialID=PER-028-15"},{"issue":"8","key":"10.1002\/14651858.CD015495-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"viii750","DOI":"10.1093\/annonc\/mdy424.077","article-title":"IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab 1 carboplatin 1 paclitaxel or nab-paclitaxel vs carboplatin 1 nabpaclitaxel in 1L advanced squamous NSCLC","volume":"29","author":"Socinski","year":"2018","journal-title":"Annals of Oncology"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD015495-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"LB512","DOI":"10.1158\/1538-7445.AM2022-LB512","article-title":"RATIONALE-304: the association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)","volume":"82","author":"Lu","year":"2022","journal-title":"Cancer Research"},{"issue":"9","key":"10.1002\/14651858.CD015495-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic non squamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD015495-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"S816","DOI":"10.1016\/j.annonc.2020.08.1577","article-title":"Tislelizumab + chemotherapy versus chemotherapy alone as first-line treatment for locally advanced\/metastatic nonsquamous NSCLC","volume":"31","author":"Lu","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0044|cit44","unstructured":"A study of atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in combination with carboplatin or cisplatin + pemetrexed compared with carboplatin or cisplatin + pemetrexed in patients who are chemotherapy-naive and have stage IV non-squamous non-small cell Lung cancer trialsearch.who.int\/Trial2.aspx?TrialID=NCT02657434"},{"key":"10.1002\/14651858.CD015495-BIB0045|cit45","unstructured":"A study of atezolizumab in combination with carboplatin or cisplatin + pemetrexed compared with carboplatin or cisplatin + pemetrexed in participants who are chemotherapy-naive and have stage IV non-squamous non-small cell lung cancer (NSCLC) (IMpower 132) clinicaltrials.gov\/ct2\/show\/NCT02657434"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD015495-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"S1386","DOI":"10.1016\/j.annonc.2020.10.369","article-title":"Final efficacy results from IMpower132: first-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC","volume":"31","author":"Nishio","year":"2020","journal-title":"Annals of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015495-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer: results from the randomized phase III IMpower132 trial","volume":"16","author":"Nishio","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015495-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/cas.14817","article-title":"IMpower132: atezolizumab plus platinum-based chemotherapy versus chemotherapy for advanced NSCLC in Japanese patients","volume":"112","author":"Nishio","year":"2021","journal-title":"Cancer Science"},{"issue":"10 Supplement","key":"10.1002\/14651858.CD015495-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S332","DOI":"10.1016\/j.jtho.2018.08.262","article-title":"IMpower132: PFS and safety results with 1L atezolizumab + carboplatin\/cisplatin + pemetrexed in stage IV non-squamous NSCLC","volume":"13","author":"Papadimitrakopoulou","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD015495-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"TPS9101","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS9101","article-title":"IMpower132: a phase III clinical program-1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC","volume":"35","author":"West","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Cheng Y Zhang L Hu J Wang D Hu C Zhou J Keynote-407 China extension study: pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC Annals of Oncology 2019 30 Suppl 9 ix201 2 10.1093\/annonc\/mdz446","DOI":"10.1093\/annonc\/mdz446.019"},{"key":"10.1002\/14651858.CD015495-BIB0052|cit52","unstructured":"Phase III study of carboplatin and paclitaxel or nano particle albumin-bound paclitaxel (nab-paclitaxel) with or without pembrolizumab in first line metastatic squamous NSCLC trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-000229-38-DE"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015495-BIB0053|cit53","first-page":"82","article-title":"Phase III study of carboplatin-paclitaxel\/nab-paclitaxel chemotherapy with or without pembrolizumab for first-line metastatic, squamous non-small cell lung carcinoma: kEYNOTE-407","volume":"4","author":"Garon","year":"2016","journal-title":"Journal of ImmunoTherapy of Cancer"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD015495-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"ix151","DOI":"10.1093\/annonc\/mdy425.002","article-title":"Carboplatin-paclitaxel\/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: results from the KEYNOTE-407 East Asia subgroup","volume":"29","author":"Kato","year":"2018","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015495-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.19.01348","article-title":"Health-related quality of life with carboplatin-paclitaxel or nab-paclitaxel with or without pembrolizumab in patients with metastatic squamous non-small-cell lung cancer","volume":"38","author":"Mazieres","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015495-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"10.1002\/14651858.CD015495-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015495-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD015495-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"v918","DOI":"10.1093\/annonc\/mdz394.080","article-title":"Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407","volume":"30","author":"Paz-Ares","year":"2019","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015495-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2018.36.15_suppl.105","article-title":"Phase 3 study of carboplatin-paclitaxel\/nabpaclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC)","volume":"36","author":"Paz-Ares","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015495-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jtho.2022.09.121","article-title":"First-line nivolumab + ipilimumab + chemotherapy in metastatic NSCLC: checkMate 9LA 3-year update","volume":"18","author":"Carbone","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0062|cit62","unstructured":"A study of nivolumab and ipilimumab combined with chemotherapy compared to chemotherapy by itself as the first treatment given for stage IV non-small cell lung cancer (NSCLC) (CheckMate 9LA) trialsearch.who.int\/Trial2.aspx?TrialID=NCT03215706"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD015495-BIB0063|cit63","first-page":"S448","article-title":"Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone for metastatic NSCLC (mNSCLC): results from CheckMate 9LA","volume":"33","author":"John","year":"2022","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD015495-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"S847","DOI":"10.1016\/j.annonc.2020.08.1625","article-title":"First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA","volume":"31","author":"John","year":"2020","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015495-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"17 (Suppl)","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA9026","article-title":"First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA","volume":"40","author":"Paz-Ares","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD015495-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"Suppl.9501","DOI":"10.1200\/JCO.2020.38.15_suppl.9501","article-title":"Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) versus 4 cycles chemo as first-line (1L) treatment (tx) for stage IV\/recurrent non-small cell lung cancer (NSCLC): checkMate 9LA","volume":"38","author":"Reck","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"174e187","DOI":"10.1016\/j.ejca.2023.01.015","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: checkMate 9LA 2-year patient-reported outcomes","volume":"183","author":"Reck","year":"2023","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10.1002\/14651858.CD015495-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2020.10.022","article-title":"OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) versus 4 cycles chemo as first-Line (1L) treatment) for stage IV\/recurrent non-small cell lung cancer (NSCLC): checkMate 9LA","volume":"16","author":"Reck","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0070|cit70","first-page":"204\u201322","article-title":"First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): 3-year update from CheckMate 9LA","volume":"18","author":"Reinmuth","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplattin and paclitaxel as first-line treatment for advanced squamous NSCLC (Camel-sq): a phase 3 trial","volume":"17","author":"Ren","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0072|cit72","unstructured":"A clinical phase III study that investigates the efficacy of atezolizumab in combination with carboplatin-paclitaxel with or without bevacizumab compared with carboplatin-paclitaxel-bevacizumab trialsearch.who.int\/Trial2.aspx?TrialID=NCT02366143"},{"key":"10.1002\/14651858.CD015495-BIB0073|cit73","unstructured":"IMpower150: efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups Oncology Research and Treatment 2018 41 4 358 10.1159\/000492737"},{"issue":"13","key":"10.1002\/14651858.CD015495-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"Abstract CT076","DOI":"10.1158\/1538-7445.AM2018-CT076","article-title":"IMpower150: efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups","volume":"78","author":"Kowanetz","year":"2018","journal-title":"Cancer Research"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD015495-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"ix177","DOI":"10.1093\/annonc\/mdy483.008","article-title":"IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations","volume":"29","author":"Mok","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0076|cit76","unstructured":"A study of atezolizumab in combination with carboplatin plus (+) paclitaxel with or without bevacizumab compared with carboplatin+paclitaxel+bevacizumab in participants with stage IV non-squamous non-small cell lung cancer (NSCLC) clinicaltrials.gov\/ct2\/show\/NCT02366143"},{"issue":"15","key":"10.1002\/14651858.CD015495-BIB0077|cit77","first-page":"1386PD","article-title":"Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) \u00b1 bevacizumab (bev) versus chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC)","volume":"36","author":"Reck","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"viii498","DOI":"10.1093\/annonc\/mdy292.009","article-title":"IMpower150: clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) 1 chemotherapy (chemo) 6 bevacizumab (bev) versus chemo 1 bev in 1L nonsquamous NSCLC","volume":"29","author":"Reck","year":"2018","journal-title":"Annals of Oncology"},{"issue":"22","key":"10.1002\/14651858.CD015495-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.19.03158","article-title":"Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer","volume":"38","author":"Reck","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015495-BIB0080|cit80","first-page":"1","article-title":"Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +\/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)","volume":"41","year":"2018","journal-title":"Oncology Research and Treatment"},{"issue":"10","key":"10.1002\/14651858.CD015495-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.jtho.2018.08.639","article-title":"IMpower150: impact of chemotherapy cycles in 1L metastatic NSCLC in patients treated with atezolizumab + bevacizumab","volume":"13","author":"Rothenstein","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"24","key":"10.1002\/14651858.CD015495-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD015495-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1200\/JCO.2018.36.15_suppl.9002","article-title":"Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) \u00b1 bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC","volume":"36","author":"Socinski","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD015495-BIB0084|cit84","first-page":"Abstract CT216","article-title":"IMpower150 final analysis: efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous(nsq) non-small cell lung cancer (NSCLC) across keysubgroups","volume":"80","author":"Socinski","year":"2020","journal-title":"American Association for Cancer Research Journals"},{"key":"10.1002\/14651858.CD015495-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"S1184","DOI":"10.1016\/j.annonc.2020.08.2287","article-title":"Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC","volume":"31(4)","author":"Lee","year":"2020","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015495-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD015495-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0088|cit88","unstructured":"A phase III clinical study to evaluate the efficacy and safety of atezolizumab in combination with carboplatin + nab-paclitaxel compared with carboplatin + nab-paclitaxel in patients with stage IV non-squamous non-small cell lung cancer trialsearch.who.int\/Trial2.aspx?TrialID=NCT02367781"},{"key":"10.1002\/14651858.CD015495-BIB0089|cit89","unstructured":"A study of atezolizumab in combination with carboplatin plus (+) nab-paclitaxel compared with carboplatin+nab-paclitaxel in participants with stage IV non-squamous non-small cell lung cancer (NSCLC) clinicaltrials.gov\/ct2\/show\/NCT02367781"},{"issue":"7","key":"10.1002\/14651858.CD015495-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncology"},{"issue":"13","key":"10.1002\/14651858.CD015495-BIB0091|cit91","first-page":"Abstract CT200","article-title":"IMpower130: progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC","volume":"79","author":"West","year":"2019","journal-title":"American Association for Cancer Research Journals"},{"key":"10.1002\/14651858.CD015495-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"Suppl 16","DOI":"10.1200\/JCO.2022.40.16_suppl.9027","article-title":"A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: a phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell","volume":"40","author":"Zhou","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD015495-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s43018-023-00578-z","article-title":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","volume":"4","author":"Zhou","year":"2023","journal-title":"Nature Cancer"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD015495-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S1386","DOI":"10.1016\/j.annonc.2020.10.368","article-title":"LBA4 GEMSTONE-302: a phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)","volume":"31","author":"Zhou","year":"2020","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD015495-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0096|cit96","unstructured":"A study of SHR-1210 in combination with pemetrexed and carboplatin in subjects with non-squamous NSCLC classic.clinicaltrials.gov\/ct2\/show\/NCT03134872"},{"issue":"5","key":"10.1002\/14651858.CD015495-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"628-39","DOI":"10.1016\/j.jtho.2022.12.017","article-title":"Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced non squamous NSCLC: extended follow-up of CameL phase 3 trial","volume":"18","author":"Zhou","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD015495-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet"},{"issue":"S1","key":"10.1002\/14651858.CD015495-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jtho.2020.10.034","article-title":"OFP01.02 KEYNOTE-021 cohort G long-term follow-up: first-line (1L) pemetrexed and carboplatin (PC) with or without pembrolizumab for advanced non squamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"12","key":"10.1002\/14651858.CD015495-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S1791","DOI":"10.1016\/j.jtho.2017.09.427","article-title":"Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous nsclc: keynote-021 cohort g update","volume":"11","author":"Borghaei","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015495-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2018.08.004","article-title":"24-month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer","volume":"14","author":"Borghaei","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"suppl 5","key":"10.1002\/14651858.CD015495-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"v636","DOI":"10.1093\/annonc\/mdx440.052","article-title":"Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC","volume":"28","author":"Borghaei","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015495-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2016.34.15_suppl.9016","article-title":"Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: kEYNOTE-021 cohorts A-C","volume":"34","author":"Gadgeel","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015495-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1200\/JCO.2018.36.15_suppl.9026","article-title":"24-month overall survival from KEYNOTE-021 cohort G: pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"36","author":"Gentzler","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"10 suppl","key":"10.1002\/14651858.CD015495-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.jtho.2019.08.426","article-title":"OA04.05 KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for non-squamous NSCLC","volume":"14","author":"Langer","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD015495-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0107|cit107","unstructured":"A study of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with non-small cell lung cancer (MK-3475-021\/KEYNOTE-021) clinicaltrials.gov\/ct2\/show\/NCT02039674 2014"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015495-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1200\/JCO.2017.35.15_suppl.9094","article-title":"First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: updated results of KEYNOTE-021 cohort G","volume":"35","author":"Papadimitrakopoulou","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015495-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1200\/jco.2015.33.15_suppl.8031","article-title":"Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as frontline therapy for advanced non-small cell lung cancer (NSCLC): kEYNOTE-021 Cohorts A and C","volume":"33","author":"Papadimitrakopoulou","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"23","key":"10.1002\/14651858.CD015495-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1111\/1759-7714.14193","article-title":"Pembrolizumab provides long-term survival benefits in advanced non-small cell lung cancer: the 5-year outcomes of the KEYNOTE-024 trial","volume":"12","author":"Li","year":"2021","journal-title":"Thoracic Cancer"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015495-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/jco.2010.28.15_suppl.7531","article-title":"Phase II trial of ipilimumab (IPI) and paclitaxel\/carboplatin (P\/C) in first-line stage IIIb\/IV non-small cell lung cancer (NSCLC)","volume":"28","author":"Lynch","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD015495-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0113|cit113","first-page":"(15)","article-title":"CA184-104: randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel\/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV\/recurrent non-small cell lung cancer (NSCLC) of squamous histology","volume":"31","author":"Reck","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD015495-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"TPS7611","DOI":"10.1200\/jco.2012.30.15_suppl.tps7611","article-title":"CA184-104: randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) with paclitaxel\/carboplatin (PC) versus placebo with PC in patients (pts) with stage IV\/recurrent non-small cell lung cancer (NSCLC) of squamous histology","volume":"30","author":"Reck","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0115|cit115","unstructured":"Efficacy and safety evaluation of sintilimab in patients with advanced or recurrent non-squamous NSCLC https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03607539 2018"},{"issue":"10","key":"10.1002\/14651858.CD015495-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic non squamous NSCLC: a randomized, double-blind, Phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD015495-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.jtho.2020.08.002","article-title":"ID: 1329 ORIENT-11: sintilimab + pemetrexed + platinum as first-line therapy for locally advanced or metastatic non-squamous NSCLC","volume":"15","author":"Zhang","year":"2020","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"9942918","DOI":"10.1155\/2022\/9942918","article-title":"Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET\/CT Features","volume":"2022","author":"Zou","year":"2022","journal-title":"Journal of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"S1186","DOI":"10.1016\/j.annonc.2020.08.2289","article-title":"ORIENT-12: sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)","volume":"31","author":"Zhou","year":"2020","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015495-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"16","author":"Zhou","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015495-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"S650","DOI":"10.1016\/j.jtho.2021.01.1189","article-title":"P80.01 A multicenter, randomized, phase 3 trial of penpulimab in combination with anlotinib or chemotherapy as first-line treatment in advanced NSCLC","volume":"16","author":"Han","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0122|cit122","first-page":"100102","article-title":"59 MO - Final analysis of AK105-302: A randomized, double-blind, placebo-controlled, phase III trial of penpulimab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC","volume":"16 (Suppl 1)","author":"Han","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0123|cit123","unstructured":"A phase III study of platinum doublet chemotherapy with or without nivolumab for the patients with chemo-naive, advanced non-small cell lung cancer (WJOG8615L) rctportal.niph.go.jp\/en\/detail?trial_id=UMIN000021136"},{"key":"10.1002\/14651858.CD015495-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Kuon J Bozorgmehr F Schneider MA Krisam J Lasitschka F Serke M Durvalumab in frail and elder patients with stage four NSCLC: the DURATION trial Annals of Oncology 2018 19 Suppl 8 viii546 7 10.1093\/annonc\/mdy292.129","DOI":"10.1093\/annonc\/mdy292.129"},{"key":"10.1002\/14651858.CD015495-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S1021-2","DOI":"10.1016\/j.annonc.2022.07.1147","article-title":"DURATION - a phase II randomized trial in older \/ frail patients (pts) with advanced non-small cell lung cancer (NSCLC) comparing chemotherapy (CTX, 4 cycles) with CTX (2 cycles) and consecutive durvalumab (D): top-line early efficacy endpoints","volume":"33","author":"Kuon","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0126|cit126","unstructured":"Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: study protocol of the randomized phase II DURATION trial clinicaltrials.gov\/ct2\/show\/NCT03345810"},{"issue":"3","key":"10.1002\/14651858.CD015495-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"S646","DOI":"10.1016\/j.jtho.2021.01.1182","article-title":"P79.03 A phase 3 study of the PD-1 inhibitor retifanlimab (INCMGA00012) plus platinum-based chemotherapy in 1L mNSCLC: POD1UM-304","volume":"16","author":"Lu","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Borghaei H Hellmann MD Paz-Ares LG Ramalingam SS Reck M O'Byrne KJ Nivolumab (Nivo) + platinum-doublet chemotherapy (chemo) versus chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PDL1 expression: results from CheckMate 227 Journal of Clinical Oncology 2018 36 15 9001","DOI":"10.1200\/JCO.2018.36.15_suppl.9001"},{"key":"10.1002\/14651858.CD015495-BIB0129|cit129","unstructured":"An investigational immuno-therapy trial of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy compared to platinum doublet chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC) clinicaltrials.gov\/ct2\/show\/NCT02477826"},{"key":"10.1002\/14651858.CD015495-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"iii50","DOI":"10.1093\/annonc\/mdx091.064","article-title":"CheckMate 227: a randomized, open-label phase 3 trial of nivolumab nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-na\u00efve patients with advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Paz-Ares L Ciuleanu TE Yu X Salman P Pluzanski A Nagrial A Nivolumab (NIVO) 1 platinum-doublet chemotherapy (chemo) versus chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): checkMate 227-part 2 final analysis Annals of Oncology 2019 30 Suppl 11 xi67 8 10.1093\/annonc\/mdz453.004","DOI":"10.1093\/annonc\/mdz453.004"},{"key":"10.1002\/14651858.CD015495-BIB0132|cit132","unstructured":"Phase II randomized trial of carboplatin+pemetrexed+bevacizumab+\/- atezolizumab in stage IV NSCLC https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03786692 2018"},{"key":"10.1002\/14651858.CD015495-BIB0133|cit133","unstructured":"Study of atezolizumab in elderly patients with advanced non-small-cell lung cancer and receiving monthly carboplatin with weekly paclitaxel chemotherapy clinicaltrials.gov\/ct2\/show\/NCT03977194"},{"key":"10.1002\/14651858.CD015495-BIB0134|cit134","unstructured":"Phase III study of HLX10 in combination with chemotherapy versus chemotherapy alone as first-line therapy for locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-003064-50-PL"},{"key":"10.1002\/14651858.CD015495-BIB0135|cit135","unstructured":"A randomized, double-blind, placebo controlled phase III study to investigate efficacy and safety of first-line treatment with HLX10 + chemotherapy (carboplatin-nanoparticle albumin bound (nab) paclitaxel) in patients with stage IIIB\/IIIC or IV NSCLC clinicaltrials.gov\/ct2\/show\/NCT04033354"},{"key":"10.1002\/14651858.CD015495-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","article-title":"Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention","volume":"10","author":"Aiello","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD015495-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.07.004","article-title":"Comparative efficacy and safety of immunotherapies targeting the PD-1\/PD- T L1 pathway for previously treated advanced non-small cell lung cancer: a Bayesian network meta-analysis","volume":"142","author":"Almutairia","year":"2019","journal-title":"Critical Reviews in Oncology \/ Hematology"},{"key":"10.1002\/14651858.CD015495-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Annals of Global Health"},{"key":"10.1002\/14651858.CD015495-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/cncr.32468","article-title":"Biomarkers for immune checkpoint inhibition in non\u2013small cell lung cancer (NSCLC)","volume":"126","author":"Bodor","year":"2020","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD015495-BIB0140|cit140","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015495-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD015495-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1002\/sim.6301","article-title":"The Peto odds ratio viewed as a new effect measure","volume":"33","author":"Brockhaus","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1002\/14651858.CD015495-BIB0145|cit145","unstructured":"Covidence Veritas Health Innovation 2020"},{"key":"10.1002\/14651858.CD015495-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"220","DOI":"10.21037\/tlcr.2018.05.06","article-title":"The epidemiology of lung cancer","volume":"7","author":"De Groot","year":"2018","journal-title":"Translational Lung Cancer Research"},{"key":"10.1002\/14651858.CD015495-BIB0147|cit147","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015495-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD015495-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nature Immunology"},{"key":"10.1002\/14651858.CD015495-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annual Review of Immunology"},{"key":"10.1002\/14651858.CD015495-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015495-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD015495-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN Guidelines Insights: Non-Small Cell Lung Cancer, version 1.2020","volume":"17","author":"Ettinger","year":"2019","journal-title":"National Comprehensive Cancer Network"},{"issue":"4","key":"10.1002\/14651858.CD015495-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"341","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines Insights: Non\u2013Small Cell Lung Cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1002\/14651858.CD015495-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ctrv.2017.08.003","article-title":"Immunosenescence and immune checkpoint inhibitors in non-small cell lung cancer patients: does age really matter?","volume":"60","author":"Ferrara","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"10.1002\/14651858.CD015495-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"492\u2013503","DOI":"10.1158\/1078-0432.CCR-20-1420","article-title":"Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy","volume":"27","author":"Ferrara","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD015495-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1183\/13993003.01695-2015","article-title":"Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy","volume":"48","author":"Fiteni","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD015495-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"874\u201384","DOI":"10.1038\/s41416-020-0986-4","article-title":"Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper","volume":"123","author":"Gomes","year":"2020","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD015495-BIB0161|cit161","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2021"},{"key":"10.1002\/14651858.CD015495-BIB0162|cit162","unstructured":"Granier C Gey A Roncelin S Weiss L Paillaud E Tartour E Immunotherapy in older patients with cancer Biomedical Journal 10.1016\/j.bj.2020.07.009"},{"key":"10.1002\/14651858.CD015495-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0164|cit164","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015495-BIB0165|cit165","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015495-BIB0166|cit166","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015495-BIB0167|cit167","unstructured":"Howlader N Noone AM Krapcho M Neyman N Aminou R Waldron W SEER cancer statistics review, 1975-2008, National Cancer Institute. Based on November 2010 SEER data submission, posted to the SEER website, 2011 seer.cancer.gov\/csr\/1975_2008\/"},{"key":"10.1002\/14651858.CD015495-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.3390\/ijms20112810","article-title":"The evolving role of CD8+CD28\u2212 immunosenescent T Cells in cancer immunology","volume":"20","author":"Huff","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD015495-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"875093","DOI":"10.3389\/fimmu.2022.875093","article-title":"Inhibitors of PD-1 in non-small cell lung cancer: a meta-analysis of clinical and molecular features","volume":"13","author":"Huo","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD015495-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD015495-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/MD.0000000000011936","article-title":"Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: meta-analysis of randomized controlled trials","volume":"97","author":"Khan","year":"2018","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/EDBK_159514","article-title":"Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"35","author":"Kluetz","year":"2016","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1002\/14651858.CD015495-BIB0173|cit173","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015495-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"909027","DOI":"10.3389\/fimmu.2022.909027","article-title":"Efficacy of atezolizumab for advanced non-small cell lung cancer based on clinical and molecular features: a meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD015495-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1194\u2013217","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Lopez-Ot\u0131n","year":"2013","journal-title":"Cell"},{"key":"10.1002\/14651858.CD015495-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/j.cllc.2020.05.004","article-title":"Efficacy and safety of anti-PD-1 immunotherapy in patients aged \u2265 75 years with non-small-cell lung cancer (NSCLC): an Italian, multicenter, retrospective study","volume":"21","author":"Luciani","year":"2020","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD015495-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD015495-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1053\/j.seminoncol.2018.08.007","article-title":"FDA analyses of survival in older adults with metastatic non\u2013small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","author":"Marur","year":"2018","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0179|cit179","unstructured":"National Comprehensive Cancer Network NCCN Non-Small Cell Lung Cancer Guidelines, Version 7.2024; 26 June 2024 www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450"},{"key":"10.1002\/14651858.CD015495-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD015495-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1270\u201383","DOI":"10.1093\/annonc\/mdu022","article-title":"Management of elderly patients with NSCLC; updated expert\u2019s opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology","volume":"25","author":"Pallis","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1002\/14651858.CD015495-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends in Immunology"},{"key":"10.1002\/14651858.CD015495-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0186|cit186","unstructured":"Paz-Ares L Ciuleanu TE Cobo M Schenker M Zurawski B Menezes J First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Lancet Oncology 10.1016\/S1470-2045(20)30641-0"},{"key":"10.1002\/14651858.CD015495-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"iv192\u2013237","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"iv1\u201321","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(11)60780-0","article-title":"Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial","volume":"378","author":"Quoix","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015495-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cllc.2019.11.004","article-title":"Predictors of survival benefit from immune checkpoint inhibitors in patients with advanced non small-cell lung cancer: a systematic review and meta-analysis","volume":"21","author":"Raphael","year":"2019","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD015495-BIB0192|cit192","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD015495-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/JTO.0b013e31827e2145","article-title":"Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?","volume":"8","author":"Sacher","year":"2013","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0194|cit194","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015495-BIB0195|cit195","unstructured":"Epidemiology and End Results Program SEER 2022 2016\u20132020, All Races, Both Sexes seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"10.1002\/14651858.CD015495-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/2229-3485.167099","article-title":"Elderly patients' participation in clinical trials","volume":"6","author":"Shenoy","year":"2015","journal-title":"Perspectives in Clinical Research"},{"key":"10.1002\/14651858.CD015495-BIB0198|cit198","unstructured":"International Society of Geriatric Oncology (Soci\u00e9t\u00e9 Internationale d\u2019Oncologie G\u00e9riatrique) Defining the elderly www.siog.org\/content\/defining-elderly"},{"key":"10.1002\/14651858.CD015495-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic non-squamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015495-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3390\/cancers12071995","article-title":"Do elderly lung cancer patients aged \u226575 years benefit from immune checkpoint inhibitors?","volume":"12","author":"Takigawa","year":"2020","journal-title":"Cancers"},{"key":"10.1002\/14651858.CD015495-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015495-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung cancer statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1002\/14651858.CD015495-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"924\u201337","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD015495-BIB0205|cit205","first-page":"307","article-title":"Lack of efficacy of immune checkpoint inhibitors in cancer patients older than 75?","volume":"45","author":"Wu","year":"2022","journal-title":"Journal of Immunotherapy"},{"key":"10.1002\/14651858.CD015495-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD015495-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015495-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3389\/fonc.2020.01671","article-title":"Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Yan","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"e196879","DOI":"10.1001\/jamanetworkopen.2019.6879","article-title":"Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis","volume":"2","author":"Yu","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD015495-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1146\u201354","DOI":"10.1007\/s12094-019-02241-5","article-title":"The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis","volume":"22","author":"Zheng","year":"2020","journal-title":"Clinical and Translational Oncology"},{"key":"10.1002\/14651858.CD015495-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"1319\u201325","DOI":"10.1093\/annonc\/mds626","article-title":"Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages","volume":"24","author":"Zhou","year":"2013","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD015495-BIB0212|cit212","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014907","article-title":"Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol","author":"Marchal","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T07:49:10Z","timestamp":1741679350000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015495"}},"subtitle":[],"editor":[{"name":"Cochrane Lung Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":212,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015495","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}